Eli Lilly is stepping up enforcement against black-market retatrutide diversion in California, signaling that supply security and compliance are becoming central to GLP-1-era pricing and access battles. The report describes limited access to cheaper insulin and suggests demand for retatrutide has pulled illicit procurement into the spotlight. In parallel, policy scrutiny around drug pricing is expanding beyond launch approvals. The enforcement storyline points to a high-stakes intersection of manufacturing, distribution constraints, and payer/price pressure—factors that can influence real-world uptake more than early clinical differentiation. For biotech leaders, the development underscores that weight-loss and metabolic portfolio execution now includes regulatory risk management and channel governance as much as pipeline performance.